会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Abeo-ergoline derivatives as 5HT1A ligands
    • 二氢麦角灵衍生物作为5HT1A配体
    • US06284896B1
    • 2001-09-04
    • US08998867
    • 1997-12-29
    • Sergio ManteganiTiziano BandieraEnzo BrambillaCarla CacciaNicola Carfagna
    • Sergio ManteganiTiziano BandieraEnzo BrambillaCarla CacciaNicola Carfagna
    • C07D48706
    • C07D487/06
    • There are provided compounds of formula (I), wherein R1 is a hydrogen, chlorine or bromine atom or a methyl, methylthio, hydroxy, cyano or carboxamido group; R2 is C1-C3 alkyl or an alkyl group; R3 and R4 are independently a hydrogen atom, a C1-C5 alkyl group, a C3-C5 alkenyl group, a C5-C6 cycloalkyl C1-C3 alkyl group, a phenyl-C3-C5 alkenyl or phenyl group: which groups are optionally substituted by C1-C3 alkyl, C1-C3 alkoxy, triflouromethyl, hydroxy or amino group; or a group of formula (a), wherein R6 is hydrogen atom or a C1-C3 alkyl group and R7 is a phenyl group, a substituted phenyl group as described above or a heterocyclic ring, R5 is a hydrogen or bromine atom or an organic residue and R is H or an organic residue, or a pharmaceutically acceptable salt thereof. A process for their preparation and the pharmaceutical compositions comprising them are also provided.
    • 提供式(I)化合物,其中R 1是氢,氯或溴原子或甲基,甲硫基,羟基,氰基或甲酰氨基; R2是C1-C3烷基或烷基; R3和R4独立地是氢原子,C1-C5烷基,C3-C5烯基,C5-C6环烷基C1-C3烷基,苯基-C3-C5链烯基或苯基:这些基团是任选取代的 C 1 -C 3烷基,C 1 -C 3烷氧基,三氟甲基,羟基或氨基; 或式(a)的基团,其中R6是氢原子或C1-C3烷基,R7是苯基,如上所述的取代苯基或杂环,R5是氢或溴原子或有机 残基,R为H或有机残基,或其药学上可接受的盐。 还提供了其制备方法和包含它们的药物组合物。
    • 6. 发明授权
    • Substituted benzylaminoalkylene heterocycles
    • 取代的苄基氨基亚烷基杂环
    • US07649005B2
    • 2010-01-19
    • US10575627
    • 2004-10-05
    • Patricia SalvatiCarla CacciaPiero MelloniAlessandra RestivoCibele Sabido DavidStefania Vallese
    • Patricia SalvatiCarla CacciaPiero MelloniAlessandra RestivoCibele Sabido DavidStefania Vallese
    • A61K31/44C07D213/02
    • C07D261/02A61K31/341A61K31/422A61K31/426C07D213/38C07D233/64C07D235/14C07D249/08C07D261/08C07D263/32C07D277/28C07D307/14C07D307/38C07D307/52C07D307/81C07D309/04C07D319/12C07D333/20
    • This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR7 group; R1 is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy; R2, R3 are independently hydrogen, C1-C6 alkyl, halogen, trifluoromethyl, hydroxy or C1-C6 alkoxy; R4 is hydrogen, C1-C8 alkyl; R5, R6 are independently hydrogen, C1-C3 alkyl, optionally substituted by hydroxy or phenyl; R7 is hydrogen or straight or branched C1-C3 alkyl; Het is a five to seven membered, saturated or unsaturated heteromonocyclic or an eight to ten membered, saturated or unsaturated heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said mono- or bicyclic groups being optionally substituted by C1-C6alkyl, halogen, hydroxyl or C1-C6 alkoxy; and the pharmaceutically acceptable salts or prodrug thereof, that are active as sodium and/or calcium channel modulators and/or as selective MAO-B inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
    • 本发明涉及通式(I)的化合物,其中X是氧或硫或NR 7基团; R 1是C 3 -C 8烷基或被苯氧基或苯基取代的C 1 -C 8烷基,苯氧基或苯基任选被一个或多个氟,氯,三氟甲基,C 1 -C 6烷基,羟基,C 1 -C 6烷氧基取代; R2,R3独立地是氢,C1-C6烷基,卤素,三氟甲基,羟基或C1-C6烷氧基; R4是氢,C1-C8烷基; R5,R6独立地为氢,任选被羟基或苯基取代的C 1 -C 3烷基; R 7是氢或直链或支链C 1 -C 3烷基; Het是五至七元饱和或不饱和杂单环或八至十元饱和或不饱和杂双环基团,其含有一个或多个独立地选自氮,氧和硫的杂原子,所述单 - 或双环基团任选被C 1 -C 1-6烷基,卤素,羟基或C 1 -C 6烷氧基; 其作为钠和/或钙通道调节剂和/或作为选择性MAO-B抑制剂是有活性的,因此可用于预防,缓解和治愈广泛范围的病症,包括但不限于 神经,精神,心血管,炎症,眼科,泌尿,代谢和胃肠疾病,其中上述机制已被描述为发挥病理作用。